Minas

Minas Therapeutics is a biotechnology company focused on developing small molecule inhibitors that target the tumor microenvironment to treat aggressive cancers and fibrotic diseases. The company's core technology centers on the C-C chemokine receptor type 2 (CCR2), a key driver in the recruitment of immunosuppressive myeloid cells to tumor sites. By inhibiting CCR2, Minas aims to disrupt the protective environment that tumors use to evade the immune system, potentially synergizing with existing checkpoint inhibitors. Their research primarily targets high-need indications such as glioblastoma and pancreatic cancer, where immune suppression is a significant barrier to treatment. The company is also exploring the application of its inhibitors in treating inflammatory and fibrotic conditions like pulmonary fibrosis. Minas Therapeutics leverages foundational research from Cedars-Sinai Medical Center to address the challenges of cold tumors.